Granulocyte Colony Stimulating Factor Attenuates Hyperoxia-Induced Lung Injury by Down-Modulating Inflammatory Responses in Neonatal Rats
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Granulocyte colony stimulating factor (G-CSF) has been known to increase neutrophil production and have anti-inflammatory properties, but the effect of G-CSF on pulmonary system is in controversy. We investigated whether G-CSF treatment could attenuate hyperoxia-induced lung injury, and whether this protective effect is mediated by the down-modulation of inflammatory responses in a neonatal rat model. Materials and Methods: Newborn Sprague-Dawley rats (Orient Co., Seoul, Korea) were subjected to 14 days of hyperoxia (90% oxygen) beginning within 10 h after birth. G-CSF (20 μg/kg) was administered intraperitoneally on the fourth, fifth, and sixth postnatal days. Results: This treatment significantly improved hyperoxia-induced reduction in body weight gain and lung pathology such as increased mean linear intercept, mean alveolar volume, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling positive cells. Hyperoxia-induced activation of nicotinamide adenine dinucleotide phosphate oxidase, which is responsible for superoxide anion production, as evidenced by upregulation and membrane translocation of p67^phox was significantly attenuated after G-CSF treatment, as were inflammatory responses such as increased myeloperoxidase activity and mRNA expression of transforming growth factor-β. However, the attenuation of other proinflammatory cytokines such as tumor necrosis factor-α and interleukin-6 was not significant. Conclusion: In sum, G-CSF treatment significantly attenuated hyperoxia-induced lung injury by down-modulating the inflammatory responses in neonatal rats.
Abstract
Purpose: Granulocyte colony stimulating factor (G-CSF) has been known to increase neutrophil production and have anti-inflammatory properties, but the effect of G-CSF on pulmonary system is in controversy. We investigated whether G-CSF treatment could attenuate hyperoxia-induced lung injury, and whether this protective effect is mediated by the down-modulation of inflammatory responses in a neonatal rat model. Materials and Methods: Newborn Sprague-Dawley rats (Orient Co., Seoul, Korea) were subjected to 14 days of hyperoxia (90% oxygen) beginning within 10 h after birth. G-CSF (20 μg/kg) was administered intraperitoneally on the fourth, fifth, and sixth postnatal days. Results: This treatment significantly improved hyperoxia-induced reduction in body weight gain and lung pathology such as increased mean linear intercept, mean alveolar volume, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling positive cells. Hyperoxia-induced activation of nicotinamide adenine dinucleotide phosphate oxidase, which is responsible for superoxide anion production, as evidenced by upregulation and membrane translocation of p67^phox was significantly attenuated after G-CSF treatment, as were inflammatory responses such as increased myeloperoxidase activity and mRNA expression of transforming growth factor-β. However, the attenuation of other proinflammatory cytokines such as tumor necrosis factor-α and interleukin-6 was not significant. Conclusion: In sum, G-CSF treatment significantly attenuated hyperoxia-induced lung injury by down-modulating the inflammatory responses in neonatal rats.
참고문헌 (39)
- Kinsella JP, "Bronchopulmonary dysplasia", Lancet, 367, pp.1421~1431 (2006)
- Short EJ, "Cognitive and academic consequences of bronchopulmonary dysplasia and very low birth weight: 8-year-old outcomes", Pediatrics, 112, pp.e359~ (2003)
- Ehrenkranz RA, "Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia", Pediatrics, 116, pp.1353~1360 (2005)
- Committee on Fetus and Newborn, "Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants", Pediatrics, 109, pp.330~338 (2002)
- "Trial of late surfactant for prevention of bronchopulmonary dysgest plasia (TOLSIRF)"[URL]
- "Trial of late surfactant to prevent BPD: A pilot study in ventilated preterm neonates receiving inhaled nitric oxide (TOLSURF Pilot)"[URL]
- Speer CP, "Inflammation and bronchopulmonary dysplasia: a continuing story", Semin Fetal Neonatal Med, 11, pp.354~362 (2006)
- Juul S, "Epo and other hematopoietic factors", Semin Fetal Neonatal Med, 12, pp.250~258 (2007)
- Weiss SJ, "Tissue destruction by neutrophils", N Engl J Med, 320, pp.365~376 (1989)
- Boneberg EM, "Molecular aspects of anti-inflammatory action of G-CSF", Inflamm Res, 51, pp.119~128 (2002)
- Shyu WC, "Functional recovery of stroke rats induced by granulocyte colony-stimulating factor-stimulated stem cells", Circulation, 110, pp.1847~1854 (2004)
- Carr R, "G-CSF and GM-CSF for treating or preventing neonatal infections", Cochrane Database Syst Rev, pp.CD003066~ (2003)
- Adach K, "Granulocyte colony-stimulating factor exacerbates the acute lung injury and pulmonary fibrosis induced by intratracheal administration of bleomycin in rats", Exp Toxicol Pathol, 53, pp.501~510 (2002)
- Miura G, "Does granulocyte colony-stimulating factor exacerbate radiation-induced acute lung injury in rats", Radiat Med, 18, pp.227~232 (2000)
- Wiedermann FJ, "Association of endogenous G-CSF with anti-inflammatory mediators in patients with acute respiratory distress syndrome", J Interferon Cytokine Res, 23, pp.729~736 (2003)
- Cooney TP, "The radial alveolar count method of Emery and Mithal: a reappraisal 1--postnatal lung growth", Thorax, 37, pp.572~579 (1982)
- Snyder JM, "Alveolarization in retinoic acid receptor-beta-deficient mice", Pediatr Res, 57, pp.384~391 (2005)
- Gray KD, "Endotoxin potentiates lung injury in cerulein-induced pancreatitis", Am J Surg, 186, pp.526~530 (2003)
- Babior BM, "NADPH oxidase: an update", Blood, 93, pp.1464~1476 (1999)
- Robinson JM, "The NADPH oxidase complex of phagocytic leukocytes: a biochemical and cytochemical view", Histochem Cell Biol, 103, pp.163~180 (1995)
- Höhler B, "NADPH oxidase subunits and superoxide production in porcine pulmonary artery endothelial cells", Histochem Cell Biol, 114, pp.29~37 (2000)
- Bland RD, "Neonatal chronic lung disease in the post-surfactant era", Biol Neonate, 88, pp.181~191 (2005)
- Kunig AM, "Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats", Am J Physiol Lung Cell Mol Physiol, 289, pp.L529~L535 (2005)
- McGrath-Morrow SA, "Apoptosis in neonatal murine lung exposed to hyperoxia", Am J Respir Cell Mol Biol, 25, pp.150~155 (2001)
- Chanock SJ, "The respiratory burst oxidase", J Biol Chem, 269, pp.24519~24522 (1994)
- Coalson JJ, "Pathology of new bronchopulmonary dysplasia", Semin Neonatol, 8, pp.73~81 (2003)
- Görgen I, "Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-alpha", J Immunol, 149, pp.918~924 (1992)
- Gross-Weege W, "Safety of a low-dosage Filgrastim (rhG-CSF) treatment in non-neutropenic surgical intensive care patients with an inflammatory process", Intensive Care Med, 23, pp.16~22 (1997)
- Knapp S, "Activation of neutrophils and inhibition of the proinflammatory cytokine response by endogenous granulocyte colony-stimulating factor in murine pneumococcal pneumonia", J Infect Dis, 189, pp.1506~1515 (2004)
- Shyu WC, "Granulocyte colony-stimulating factor for acute ischemic stroke: a randomized controlled trial", CMAJ, 174, pp.927~933 (2006)
- Hartung T, "Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers", Blood, 85, pp.2482~2489 (1995)
- Donini M, "G-CSF treatment of severe congenital neutropenia reverses neutropenia but does not correct the underlying functional deficiency of the neutrophil in defending against microorganisms", Blood, 109, pp.4716~4723 (2007)
- Carr R, "Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial", Lancet, 373, pp.226~233 (2009)
- Minnerup J, "Granulocyte-colony stimulating factor for stroke treatment: mechanisms of action and efficacy in preclinical studies", Exp Transl Stroke Med, pp.1~2 (2009)
- 김봉림, "Granulocyte Stimulating Factor Attenuates Hypoxic-ischemic Brain Injury by Inhibiting Apoptosis in Neonatal Rats", Yonsei Medical Journal, 49(5), pp.836~842 (2008), 연세대학교의과대학
- Saugstad OD, "Bronchopulmonary dysplasia-oxidative stress and antioxidants", Semin Neonatol, 8, pp.39~49 (2003)
- Bastian NR, "Assembly and regulation of NADPH oxidase and nitric oxide synthase", Curr Opin Immunol, 6, pp.131~139 (1994)
- Chang YS, "alpha-PHENYL-N-tert-BUTYLNITRONE ATTENUATES HYPEROXIA-INDUCED LUNG INJURY BY DOWN-MODULATING INFLAMMATION IN NEONATAL RATS", EXPERIMENTAL LUNG RESEARCH, 35(3), pp.234~249 (2009), TAYLOR FRANCIS INC
- Delacourt C, "Oxidant-antioxidant balance in alveolar macrophages from newborn rats", Eur Respir J, 9, pp.2517~2524 (1996)